Population‑based registry analysis of cervical cancer trends in Tashkent Uzbekistan 2014-2024.

Authors

Ulugbek Khudayberdievich Mirzaev, Jasur Ravshanovich Juraev, Iroda Pulatovna Sharipova, Sarvar Temurovich Islomov, Nodira Isroilovna Tursunova, Sitora Rakhmatova, Fatima Shokir Qizi Shodieva, Mirzarakhim Mirzakhakimovich Baynazarov, Khasanjon Kobiljon Ugli Odilov, Dilbar Yuldashevna Yuldasheva, Golib Abdulloyevich Khakimov

Published in

JNCI cancer spectrum. Oct 09, 2026. Epub Oct 09, 2026.

Abstract

Cervical cancer remains a leading cause of morbidity and mortality among women in Uzbekistan, exceeding WHO elimination targets. Despite a school-based HPV vaccination program launched in 2019, screening coverage remains low, leading to delayed diagnoses; we examined cervical cancer trends in Tashkent (2014-2024) to evaluate the impact of the Korea Foundation for International Healthcare (KOFIH) screening project and UNFPA/UNDP HPV testing initiatives.
We analyzed Tashkent City Oncoregister data for women diagnosed with invasive cervical cancer or carcinoma in situ (CIS) between 2014 and 2024 (n = 2,140) after data cleaning. We calculated age-standardized incidence and mortality rates, assessed survival using Kaplan-Meier methods, and identified mortality predictors using Cox regression models.
The age-standardized incidence of invasive cervical cancer was 14.9 per 100,000. After KOFIH and UNFPA/UNDP implementation, CIS diagnoses increased 3.4-fold (0.2 to 4.7 per 100,000), while the proportion of advanced-stage (III-IV) disease declined by 43%. Five-year survival showed clear stage dependence, ranging from 91.5% for CIS to 27.8% for stage IV. Age and stage were independent predictors of mortality. Crude mortality declined from 10.2 to 1.1 per 100,000 from 2014 to 2024, and case fatality decreased from 48.6% (2014-2019) to 27.2% (2020-2024).
Organized screening through KOFIH and UNFPA initiatives can improve early detection and reduce mortality. However, 76.6% of staged invasive cases remain advanced (II-IV), and more than 80% of women have never been screened, underscoring the need to expand screening, sustain HPV vaccination, and strengthen prevention programs in Central Asia.

PMID:
42853092
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.